Gmt Capital Corp Vaxart, Inc. Transaction History

Gmt Capital Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$5.77 - $7.96 $3.26 Million - $4.49 Million	-564,243 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$6.67 - $9.8 $695,014 - $1.02 Million	104,200 Added 22.65%	564,243 $4.49 Million
Q2 2021 Aug 13, 2021	BUY	$5.06 - $10.78 $2.33 Million - $4.96 Million	460,043 New	460,043 $3.45 Million
Q4 2020 Feb 09, 2021	SELL	$3.5 - $7.98 $1.57 Million - $3.57 Million	-447,800 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.78 - $16.97 $2.14 Million - $7.6 Million	447,800 New	447,800 $2.98 Million

108

40.6M

96.7K

239K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $104M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.